Efficacy of a surveillance program for early detection of hepatocellular carcinoma

Istituto di Clinica Medica Generale e Terapia Medica, University of Bologna, Italy.
Cancer (Impact Factor: 4.89). 09/1996; 78(5):977-85. DOI: 10.1002/(SICI)1097-0142(19960901)78:5<977::AID-CNCR6>3.0.CO;2-9
Source: PubMed


Contrasting data have so far been reported on the utility and efficacy of screening patients with cirrhosis for early detection of hepatocellular carcinoma (HCC). The goal of this study was to evaluate the efficacy of a regular ultrasonographic and laboratory follow-up for the early detection of small HCC, and to identify parameters correlated with a higher risk of developing HCC.
One hundred and sixty-four consecutive patients with liver cirrhosis living in Emilia Romagna, Italy, were enrolled in the period 1989-1991. All patients underwent clinical, biochemical, and ultrasonographic evaluations at entry and at 3- and 6-month intervals during follow-up.
By April 1995, 34 patients had developed HCC. In 76% of the patients, ultrasonography identified HCC when it was still single and small (< 4 cm). At discriminant, logistic regression and univariate analyses, sex and the entry concentration of alkaline phosphatase, alpha-fetoprotein, gamma-glutamyl transpeptidase, and albumin were associated with a higher risk of developing HCC, whereas at multivariate analysis (Cox's model), only sex and the entry concentration of alkaline phosphatase, albumin, and alpha-fetoprotein were independently and significantly related to the appearance of HCC.
A regular ultrasonographic follow-up, timed at 3- to 6-month intervals according to the risk of HCC development in patients with cirrhosis, allows the detection of liver carcinoma at an early stage in a high proportion of patients, possibly improving the prognosis of the disease.

Download full-text


Available from: Giampaolo Bianchi, Oct 09, 2014
  • Source
    • "The early diagnosis of cancer is crucial for patient survival [1]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cadmium sulfide (CdS) quantum dots (QDs) were coupled to an Au nanoimmunosensor on a quartz crystal microbalance (QCM) to form the basis of an ultrasensitive and label-free sensor of annexin A3 (ANXA3), a lung and prostate cancer biomarker protein. Polyclonal anti-ANXA3 antibody was covalently immobilized on the CdS QDs, which had previously been functionalized with carboxyl groups and bound to a cystamine self-assembled monolayer on the Au/QCM. Frequency changes induced by the binding of ANXA3 to the anti-ANXA3 on the probe's surface allowed the very sensitive detection of GST-ANXA3 with a detection limit of 0.075 ± 0.01 ng/mL. The sensor could detect ANXA3 at 0.1 ng/mL in spiked human blood and urine samples in less than 15 min without any interference from other proteins.
    Full-text · Article · Oct 2013 · Sensors and Actuators B Chemical
  • Source
    • "Alpha-fetoprotein (AFP) was first described about 40 years ago and is proposed as a screening and diagnostic tool for HCC [14-19]. Recently, the national comprehensive cancer network guidelines also proposed AFP as a alternative tool for diagnosing HCC [20]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background/Aims Alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) have been used as diagnostic tools for hepatocellular carcinoma (HCC). However, prediction of outcome using AFP and DCP has not been elucidated. We investigated the clinical role of AFP and DCP as predictors of treatment outcome in patients with HCC undergoing trans-arterial chemoembolization (TACE). Methods Between January 2003 and December 2005, we enrolled 115 treatment-naïve patients who received TACE as an initial treatment modality. An AFP or DCP response was defined as a reduction of more than 50% from the baseline level 1 month after TACE. Patients with AFP < 20 ng/mL or DCP < 20 mAU/mL were excluded. Results The median age was 59 years and the male gender predominated (n = 81, 70.4%). AFP and DCP response was identified in 91 (79.1%) and 77 (66.9%) patients after TACE. Although progression-free survival (PFS) did not differ according to AFP response (P = 0.150), AFP responders showed significantly better overall survival (OS) than non-responders (34.9 vs. 13.2 months; P = 0.002). In contrast, DCP response did not influence either PFS or OS (all P > 0.05). Multivariate analyses showed that gamma-glutamyltranspeptidase and baseline AFP were predictors of PFS (all P < 0.05) and that male gender, the presence of liver cirrhosis, baseline DCP, number of measurable tumors and AFP response were independent predictors of OS (all P < 0.05). Conclusions AFP response and higher baseline DCP level are significant predictors of OS in treatment-naïve patients with HCC receiving TACE who showed pretreatment elevation of both AFP and DCP.
    Full-text · Article · Jan 2013 · BMC Cancer
  • Source
    • "Alpha-fetoprotein (AFP), together with hepatic ultrasonography, is the most common marker used in clinical practice to detect HCC in cirrhotic patients, and has been considered the gold-standard serum marker for screening patients at high risk for HCC, as well as for the diagnosis and monitoring of responses to HCC treatment for over 40 years. But the clinical value of AFP is challenged in recent years due to low sensitivity and specificity [3-5]. In addition, AFP levels greater than 500 ng/ml are correlated with the tumor size: 80% of small HCC show no increase of AFP concentration [6]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There have been conflicting reports about serum golgi protein 73 (GP73) as one of the most promising serum markers for the diagnosis of hepatocellular carcinoma (HCC). This study was to make a systematic review about the diagnostic accuracy of serum GP73 versus alpha-fetoprotein (AFP) for HCC. After a systematic review of related studies, sensitivity, specificity and other measures about the accuracy of serum GP73 and AFP in the diagnosis of HCC were pooled using random-effects models. Summary receiver operating characteristic curve analysis was used to summarize the overall test performance. Eight studies were included in our meta-analysis. The summary estimates for serum GP73 and AFP in diagnosing HCC in the studies included were as follows: sensitivity, 76% (95% confidence interval (CI) 51-91%) vs. 70% (47-86%); specificity, 86% (95%CI 65-95%) vs. 89% (69-96%); diagnostic odds ratio (DOR), 18.59 (95%CI 5.33-64.91) vs. 18.00(9.41-34.46); and area under sROC, 0.88 (95%CI 0.77-0.99) vs. 0.86 (95%CI 0.84-0.87). The current evidence indicates that serum GP73 has a comparable accuracy to AFP for the diagnosis of HCC, while the value of serum GP73 in combination with AFP for HCC detection deserves further investigation.
    Full-text · Article · Jan 2012 · BMC Cancer
Show more